Viking's latest program seeks to push the envelope in weight loss efficacy. The human appetite has more than one off switch, and drugmakers like Eli Lilly ( LLY -1.37%) and Novo Nordisk ( NVO -1.17%) ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Lian indicated the oral VK2735 program is expected to advance into Phase III for obesity, with initiation targeted for the third quarter of 2026. "We currently expect to initiate this program in the ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Results from VENTURE Phase 2 Study of Subcutaneous VK2735 in Obese Patients and Phase 1 Trial of Oral VK2735 in Healthy Subjects to be Presented SAN DIEGO, Oct. 28, 2024 /PRNewswire/ -- Viking ...
First, a bit of detail about these products and potential products. Lilly's drugs -- Mounjaro and Zepbound -- involve the molecule tirzepatide, which acts on glucagon-like peptide-1 (GLP-1) and ...
Ligand Pharmaceuticals delivered notice to Viking Therapeutics that it was terminating the TR-Beta Program. Ligand said it was terminating the program as a result of its claim that Viking "materially ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results